HC Advisors LLC Makes New Investment in Johnson & Johnson (NYSE:JNJ)

HC Advisors LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,476 shares of the company’s stock, valued at approximately $213,000.

A number of other hedge funds have also recently made changes to their positions in JNJ. Janus Henderson Group PLC grew its position in Johnson & Johnson by 228.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock valued at $549,223,000 after purchasing an additional 2,356,359 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after buying an additional 1,729,281 shares during the last quarter. Holocene Advisors LP bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $225,040,000. FMR LLC raised its holdings in Johnson & Johnson by 7.4% in the 3rd quarter. FMR LLC now owns 18,316,920 shares of the company’s stock worth $2,968,440,000 after acquiring an additional 1,265,748 shares during the last quarter. Finally, Proficio Capital Partners LLC lifted its position in Johnson & Johnson by 7,516.1% in the 4th quarter. Proficio Capital Partners LLC now owns 1,245,771 shares of the company’s stock valued at $180,163,000 after acquiring an additional 1,229,414 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $165.23 on Friday. The stock has a market cap of $397.81 billion, a P/E ratio of 24.85, a P/E/G ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock’s fifty day moving average is $150.90 and its 200 day moving average is $156.04. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.29 earnings per share. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. Johnson & Johnson’s payout ratio is currently 74.59%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JNJ. Stifel Nicolaus decreased their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Raymond James decreased their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Barclays raised their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Finally, Guggenheim raised their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.